The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial

BACKGROUND: The phase II CIGMA trial performed in 160 patients with severe community-acquired pneumonia (sCAP) found treatment with trimodulin (human polyvalent immunoglobulin [Ig]: ~ 23% IgM, ~ 21% IgA, ~ 56% IgG) was associated with a lower mortality in those patients with elevated baseline serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Mervyn, Torres, Antoni, Heinz, Corina C., Weißmüller, Sabrina, Staus, Alexander, Kistner, Steffen, Jakubczyk, Ksenia, Häder, Thomas, Langohr, Patrick, Wartenberg-Demand, Andrea, Schüttrumpf, Jörg, Vincent, Jean-Louis, Welte, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634136/
https://www.ncbi.nlm.nih.gov/pubmed/37946226
http://dx.doi.org/10.1186/s13054-023-04719-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634136/
https://www.ncbi.nlm.nih.gov/pubmed/37946226
http://dx.doi.org/10.1186/s13054-023-04719-9

Ejemplares similares